Skip to content

Improving Heart Health in Appalachia

Reducing Health Disparities in Appalachians With Multiple Cardiovascular Disease Risk Factors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01884246
Acronym
HeartHealth
Enrollment
330
Registered
2013-06-21
Start date
2013-08-01
Completion date
2016-12-31
Last updated
2017-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Hyperlipidemia, Hypertension, Obesity

Keywords

lifestyle change, behavior change, obesity, hypertension, hyperlipidemia, physical inactivity, depression

Brief summary

Individuals in Appalachian Kentucky are vulnerable to cardiovascular disease (CVD) by virtue of having high rates of multiple CVD risk factors. There is a critical need to develop and test CVD risk reducing interventions that are appropriate and effective in Appalachia. In the absence of such interventions, the dramatic CVD disparities seen in this area will continue to rise. Lifestyle interventions reduce CVD risk by 44%. The investigators and others have demonstrated that lifestyle change is most effective when patients are given the tools to engage in effective self-care, and that interventions individualized to patients' specific needs and barriers are more effective than interventions that are not. The central hypothesis is that to be successful in Appalachia, CVD risk reducing interventions must focus on patient-centered lifestyle change that increase individuals' abilities to engage in self-care, must be culturally appropriate, and must have components that overcome barriers faced by individuals living in Appalachia. The investigators propose a randomized, controlled comparative effectiveness trial with 300 individuals from Appalachian Kentucky who do not have a primary care provider and who are at risk for CVD by virtue of having two or more modifiable CVD risk factors. The investigators will compare (1) a patient-centered, culturally appropriate, self-care CVD risk reduction intervention (HeartHealth) designed to improve multiple CVD risk factors while overcoming barriers to success with (2) referral of patients to a primary care provider for management of their CVD risk factors. The investigators propose the following specific aims to be tested at 4 months and 1 year after baseline. To compare the short and long-term impact of the interventions on: 1\) the risk factor selected by patients (i.e., tobacco use, blood pressure, lipid profile, hemoglobin-A1c (HgA1c) for diabetics, body mass index, waist circumference, depressive symptoms, or physical activity level); 2) all of the CVD risk factors of each patient; 3) quality of life; 4) patient and healthcare provider satisfaction; 5) desirability and adoptability by assessing adherence to recommended CVD risk reduction measures, and retention of recruited individuals. The investigators hypothesize that in comparison to the referral strategy, the multifaceted patient-centered, self-care intervention will engender more favorable outcomes across all measures.

Interventions

BEHAVIORALSelf-care CVD risk reduction

A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.

OTHERReferral to primary care provider for CVD risk management

The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Sponsors

University of Kentucky Center for Excellence in Rural Health-Hazard
CollaboratorUNKNOWN
Debra Moser
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* residents of eastern Appalachian Kentucky * do not have a primary care provider * at risk for CVD as reflected by having two or more of the following modifiable risk factors 1. clinical diagnosis of hypertension or taking medications diagnosed for hypertension or found to be hypertensive on screening; 2. clinical diagnosis of hyperlipidemia or taking medication for treating abnormal lipid levels, or any lipid abnormality found on screening that indicates hyperlipidemia; 3. diagnosis of type 2 diabetes or HgA1c \> 7% found on screening; 4. overweight or obese (body mass index ≥ 25 kg/m2); 5. waist circumference \> 40 inches in men or \> 35 inches in women; 6. clinical diagnosis of depression, on medications for depression or found to have depressive symptoms (score of \> 9 on the Patient Health Questionnaire-9) by baseline screening; 7. sedentary lifestyle meaning that the individual does not engage in at least 30 minutes of moderate activity for at least 4 days per week

Exclusion criteria

* known coronary artery disease, cerebrovascular disease, history of acute coronary syndrome or peripheral arterial disease; * taking medications (e.g., protease inhibitors) that interfere with lipid metabolism; * cognitive impairment that precludes an individual from understanding the consent process, answering questionnaires, or participating in the intervention; * chronic drug abuse; * end-stage renal or liver or pulmonary disease; * current active cancer (i.e., undergoing active treatment for cancer) other than isolated skin cancer treatable by simple excision; * gastrointestinal disease that requires special diets (e.g., Crohn's disease; celiac disease)

Design outcomes

Primary

MeasureTime frameDescription
cardiovascular risk factor selected by patient4 monthsPatient selects their own risk reduction goal from the following: smoking, blood pressure, lipid profile, body mass index, hemoglobin-A1c for diabetics, depression, physical activity level, waist circumference

Secondary

MeasureTime frameDescription
all CVD risk factors of each patient4 monthsAll CVD risk factors that each patient has are secondary outcomes

Other

MeasureTime frame
quality of life4 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026